2021 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma.
2021 ASCO genitourinary cancer symposium
HIF-2α inhibitor
Renal cell carcinoma
VEGFR-TKI
first-line
immunotherapy
Journal
Expert review of anticancer therapy
ISSN: 1744-8328
Titre abrégé: Expert Rev Anticancer Ther
Pays: England
ID NLM: 101123358
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
pubmed:
7
9
2021
medline:
4
3
2022
entrez:
6
9
2021
Statut:
ppublish
Résumé
The 2021 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium represents an unmissable event for oncologists who deal with renal cell carcinoma (RCC). This article describes the main acquisitions of RCC management, including the advent of a new combo (pembrolizumab+lenvatinib) as first-line therapy, the confirmation of an OS advantage of ICI plus VEGFR-TKI combinations over sunitinib at longer follow-up, the persistent benefit from these combinations in particular subgroups (clear cell mRCC tumors with sarcomatoid differentiation), and possible new approaches in subsequent lines of therapy (including the HIF-2α inhibitor belzutifan). This 2021 ASCO Genitourinary Cancer Symposium laid the foundations for further knowledge development necessary for an increasingly personalized management of mRCC.
Sections du résumé
BACKGROUND
The 2021 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium represents an unmissable event for oncologists who deal with renal cell carcinoma (RCC).
AIM AND RESULTS
This article describes the main acquisitions of RCC management, including the advent of a new combo (pembrolizumab+lenvatinib) as first-line therapy, the confirmation of an OS advantage of ICI plus VEGFR-TKI combinations over sunitinib at longer follow-up, the persistent benefit from these combinations in particular subgroups (clear cell mRCC tumors with sarcomatoid differentiation), and possible new approaches in subsequent lines of therapy (including the HIF-2α inhibitor belzutifan).
CONCLUSIONS
This 2021 ASCO Genitourinary Cancer Symposium laid the foundations for further knowledge development necessary for an increasingly personalized management of mRCC.
Identifiants
pubmed: 34482771
doi: 10.1080/14737140.2021.1976147
doi:
Substances chimiques
Antineoplastic Agents
0
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM